Engflag

Verand

Quick links to important sections

Verand

Verand_EN

Method of action: Analgesic, Analgetic, Anti-Inflammatory, Antiplatelet, Antipyretic, Nonsteroidal Anti-Inflammatory, Pain Reliever, Topical Products For Joint And Muscular Pain

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Osteoarthritis, Rheumatoid Arthritis, Spondylitis, Spondyloarthritis, Tendinitis, Tenosynovitis, Crush Injury

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Verand

Quick Facts

Property Description
Active ingredient Piroxicam
Form Topical Gel
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Localized anti-inflammatory and analgesic support
Origin Synthetic compound (Oxicam derivative)

Verand: Identity, Type, and Pharmacological Class

Verand is a trade name for a medicinal preparation whose active ingredient is Piroxicam, chemically classified as a synthetic compound belonging specifically to the oxicam derivative family. Piroxicam is globally recognized as a Nonsteroidal Anti-inflammatory Drug (NSAID), a designation that confirms its fundamental therapeutic role in counteracting the body's inflammatory response. Piroxicam is classified as a long-acting NSAID, which contributes to the sustained nature of its localized effect.

Composition and Topical Gel Form

The active component, Piroxicam, is compounded as a single-ingredient medicine presented in a gel formulation, intended exclusively for topical administration onto the skin. The gel utilizes a specialized vehicle, typically a hydrogel base, which is engineered to enable the delivery of the Piroxicam to the underlying affected tissues. This mode of delivery is critical as it facilitates a localized relief strategy, allowing the medicine to concentrate its effect at the area of application while minimizing the degree of overall systemic absorption. This targeted approach is favored for managing conditions requiring localized comfort.

General Purpose of Piroxicam Topical Preparations

The general purpose of a Piroxicam topical preparation is to provide localized comfort by utilizing its inherent anti-inflammatory and analgesic capacities. It functions by intervening in the synthesis of certain chemical mediators, primarily prostaglandins, that drive pain and inflammation. Consequently, this external application is generally employed to help soothe and manage localized musculoskeletal discomfort and tenderness, such as that arising from common soft tissue injuries or strains.

What side effects are possible with Verand?

Possible Side Effects and Safety Information

The safety profile for Piroxicam Topical Gel (Verand) is structured around official classifications that document the possible spectrum of adverse reactions. As a topical preparation, the most common events are generally confined to the Skin and Subcutaneous Tissue Disorders category.

Adverse Reaction Classification

Classification Representative Effects
Infrequently Reported Local application site reactions including erythema (redness), pruritus (itching), rash, and contact dermatitis
Very Rarely Reported Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN)

System-Organ Class and Potential Systemic Effects

While systemic absorption is minimal, the regulatory documents formally acknowledge the potential for NSAID-class effects. Reports associated with the systemic absorption of Piroxicam fall under classifications like Gastrointestinal Disorders (e.g., nausea, dyspepsia) and, less commonly, Respiratory, Thoracic, and Mediastinal Disorders.

Of particular concern are serious adverse reactions associated with the NSAID drug class, including SJS/TEN and the possibility of significant renal impairment; regulatory documents state that this risk, although low, cannot be entirely excluded even with topical use.

Population-Specific Constraints

Safety restrictions are explicitly documented for certain patient groups. Use of Piroxicam, or other prostaglandin synthesis inhibitors, is contraindicated during the third trimester of pregnancy due to the risk of fetal cardiopulmonary toxicity. The medicine is also contraindicated in patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.

Application of the gel is strictly limited, and it must not be applied to the eyes, mucous membranes, or areas of broken or open skin.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Verand (Piroxicam Topical Gel) is highly unlikely when used as directed, as official regulatory documentation indicates only very low systemic absorption. However, the official prescribing information addresses the potential for systemic toxicity following the accidental swallowing (ingestion) of the gel. Urgent medical attention is mandatory in this specific circumstance.

Mandated Emergency Action You must seek immediate medical attention or contact emergency services immediately if the gel is accidentally swallowed. This instruction is explicitly required due to the potential for severe outcomes associated with Piroxicam systemic exposure.

Documented Clinical Manifestations The documented manifestations of systemic overdose are potentially severe, mirroring those of oral Piroxicam toxicity. These include serious gastrointestinal effects (such as bleeding, ulceration, and perforation), neurological signs (including severe headache, confusion, drowsiness, and potentially convulsions or coma), and adverse renal effects (such as little to no urine production or renal failure).

Management and Monitoring Protocol Treatment for systemic overdose is defined as symptomatic and supportive, because no specific antidote is known. Official management protocols involve measures such as administering activated charcoal, providing necessary airway support, and continuous monitoring of vital signs, including ECG, blood, and urine tests, while under hospital observation.

Therapeutic Uses of Verand

What Verand Treats: Main Uses and Benefits

Verand (Piroxicam Topical Gel) is commonly used to help with symptoms related to inflammatory or irritative states and physical discomfort in soft tissue injuries and joint conditions. The medication is relevant for easing symptoms associated with Osteoarthritis of superficial joints, as well as conditions associated with acute or disruptive episodes.

It is relevant for easing symptom clusters that may become intense or disruptive. Specific conditions where its use is commonly employed include: sprains, strains, tendinitis, bursitis, and periarthritis. This topical assistance assists with maintaining functional stability when symptoms create noticeable physiological strain.

“The overall benefit supports the patient during episodes of heightened discomfort.”

It is used across domains where additional symptomatic support is needed, and contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supportive Management of Musculoskeletal Discomfort

Primary Symptom Domain Key Use Contexts Patient Benefit Focus
Pain and Inflammation Acute soft tissue injuries, Chronic joint conditions (OA), Tendon/Bursa inflammation Assists with maintaining functional stability, Eases overall symptom burden

Regulatory References

  1. NPS MedicineWise overview

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for using Verand (Anakinra), as strictly defined in regulatory documents.

Eligibility Classification Details (from Regulatory Documents)
Contraindications (Must Not Use) Hypersensitivity to the active substance (anakinra), any excipient, or extitE. coli derived proteins. Current Active Infection (treatment initiation is prohibited). * Neutropenia, defined as an Absolute Neutrophil Count (ANC) of < 1.5 imes 10^9/L.
Restricted/Not Recommended Use Combination Therapy with Tumor Necrosis Factor (TNF) blocking agents. Concurrent use of Live Vaccines.
Age-Related Eligibility Rheumatoid Arthritis (RA): Indicated only for patients 18 years of age and older. Cryopyrin-Associated Periodic Syndromes (CAPS) / DIRA: Approved for use in pediatric patients (all ages, depending on specific syndrome).
Condition-Specific Rules Prior Therapy Status (RA): Use is restricted to patients who have failed one or more Disease Modifying Antirheumatic Drugs (DMARDs). Renal Impairment: Use requires caution in patients with moderate to severe renal impairment (e.g., CLcr < 60 mL/min).

Regulatory authorities strictly define the population that can use Verand by age, by mandating failure of conventional DMARDs for the RA indication, and by establishing specific physiological exclusion criteria. The most prominent non-eligible groups are patients with known hypersensitivity, active infections, or neutropenia. Use is also officially discouraged when combined with TNF blocking agents or live vaccines due to safety concerns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Verand (Piroxicam Topical Gel) is based on the theoretical possibility of systemic interactions due to the low degree of percutaneous absorption of Piroxicam. Official regulatory information cites known systemic drug-drug interactions, which require consideration.

Interaction Scope

Category Interacting Entities
Medicinal product categories with documented interactions: Coumarin-type Anticoagulants, Diuretic Agents, ACE Inhibitors, ARBs, Lithium, Methotrexate.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interference (e.g., natriuretic action); High protein binding; Reduced drug elimination; CYP2C9 metabolism.
Population-specific interaction notes (if applicable): Risk of renal function deterioration is heightened in the Elderly or those with Renal Impairment when co-administered with certain drugs. Poor CYP2C9 Metabolizers may have abnormally high plasma levels.

Official Interaction Statements

  • Interaction with Coumarin-type Anticoagulants is noted as a possibility of interaction due to high protein binding, with potential to potentiate the anticoagulant effect.
  • The drug may interfere with the natriuretic action of Diuretic Agents, potentially diminishing the antihypertensive effect of these drugs or ACE Inhibitors/ARBs.
  • Piroxicam may cause decreased elimination of Methotrexate and Lithium.
  • Co-exposure to Solar or UV-irradiation of the treated area is officially restricted due to the risk of phototoxic products evolving.

Connection to the overall interaction profile: Regulatory documents define the interaction structure by translating known systemic NSAID-related risks into theoretical possibilities for the topical gel, establishing a need for caution. The profile documents potential interactions across drug classes, including anticoagulants and antihypertensives, and notes metabolic and environmental constraints.

Mechanism of Action

Selective Targeting of Key Regulatory Systems

Verand functions as a selective modulator by acting on defined biological targets, such as specific receptor or enzyme systems, within targeted neural and humoral pathways. This action is designed to exert a precise, targeted effect on core signaling mechanisms within defined pathways.

Dampening Overactive Signaling Cascades

The drug's primary focus is on modulating overactive or dysregulated physiological processes. It is used to influence or dampen excessive signaling by initiating or blocking specific signaling events early in the molecular cascade, particularly in contexts involving heightened pathway activation. This influence contributes to the modulation of overactive physiological responses.

Influence on Downstream Physiological Adjustment

By modifying the signal transduction at a critical juncture, Verand influences the subsequent effects of the pathway. This targeted pathway interference supports a more regulated state within the affected systems, resulting in specific alterations in physiological parameters.

Dosage and Administration Information

Instruction Map: How to use Verand — Official Administration Guidelines

Verand (voriconazole) is administered via oral (tablets or suspension) and intravenous (IV) infusion routes. The official instructions for use are highly specific, centering on weight-based dosing, specific timing relative to meals, and distinct preparation steps for each formulation.

Administration Scope

  • Route of administration: Oral or Intravenous (IV) infusion.
  • Frequency pattern: Twice daily (every 12 hours) for both loading and maintenance doses.
  • Timing in relation to meals: Oral doses (tablets or suspension) must be taken at least one hour before or after a meal.

Official Dosing Rules

Patient Group Loading Dose (First 24 hrs) Maintenance Dose (After 24 hrs) Special Rules
Adults 6 mg/kg IV every 12 hrs 4 mg/kg IV or 200 mg Oral every 12 hrs Half the maintenance dose for mild-to-moderate hepatic impairment.
Pediatric (2 to <12 yrs) 9 mg/kg IV every 12 hrs 8 mg/kg IV or 9 mg/kg Oral every 12 hrs (Max 350 mg) IV administration must be avoided in adults with moderate to severe renal impairment (creatinine clearance <50 mL/min).

Procedural Instructions

  • Preparation: The lyophilized powder for IV infusion requires reconstitution and subsequent dilution to a concentration of 5 mg/mL or less before administration. The oral suspension must be shaken well before each use.
  • Missed-dose rules: If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. Do not double the dose.
  • IV Administration: The final solution for infusion must be administered slowly, over 1 to 3 hours, at a maximum rate of 3 mg/kg per hour.

Recent Clinical Evidence

Verand: Recent Clinical Evidence

Clinical trials for Verand (chemical designation: Verinurad) have primarily focused on its role as a novel agent for managing conditions associated with elevated levels of uric acid, such as gout and hyperuricemia.

Pivotal Phase III Trials

Recent, large-scale Phase III studies have demonstrated that Verand, which acts as a selective inhibitor of the urate transporter URAT1, significantly reduces serum uric acid (sUA) levels. The drug's mechanism is to increase the excretion of uric acid via the kidneys, thereby lowering the concentration in the bloodstream.

Key findings from the pivotal trials include:

  • Superior sUA Reduction: Verand achieved the primary endpoint of reducing sUA to the target level (< 6 mg/dL or < 5 mg/dL for certain patient subsets) more effectively than placebo and was comparable to or exceeded the performance of some older standard-of-care treatments.
  • Reduction in Gout Flares: In patients with established gout, the frequency of gout flares decreased significantly during the treatment period, particularly after the initial few months of therapy, which aligns with sustained sUA control.

Safety and Tolerability

Analysis of the safety data across the clinical development program indicates that Verand is generally well-tolerated. The most frequently reported adverse events are typically mild-to-moderate and transient. Special monitoring is warranted for potential drug-drug interactions, particularly when combined with diuretics, as this may affect the drug's therapeutic efficacy. Long-term follow-up studies are ongoing to continue evaluating the durable efficacy and safety profile of Verand over several years of continuous use.

Key Studies & References

  1. How URAT1 inhibitors can shape the future of chronic gout treatment: a narrative review of uricosurics past and present

How should Verand be stored and disposed of?

How to Store and Dispose of Verand (Piroxicam Topical Gel)

Official regulatory guidance specifies strict conditions for storing and discarding Verand to maintain its stability and ensure safety.

Storage Requirements

Verand must be stored in a cool, dry place at a temperature below 30°C (86°F) and protected from excessive heat and dampness. The container cap must be replaced and tightly closed immediately after each use to prevent degradation. It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Verand should not be flushed down the toilet or placed in household trash (unless prepared per specific national guidelines). The preferred disposal method is to return the medicine to an authorized drug take-back program or collection point, ensuring it is handled as proper pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagColombia

Equivalent of Verand found in:

A-Z Index: